Indegene | Business Upturn

Indegene shares rise over 2% as Q3 revenue jumps 30.8% YoY to Rs 942 crore, EBITDA up 21%

Aman Shukla — Fri, 30 Jan 2026 04:23:43 +0000

Shares of Indegene gained over 2% in early morning trade on Friday after the company reported its Q3 FY26 consolidated financial results. The stock opened at ₹464.00 and moved to an intraday high of ₹480.45, compared with the previous close of ₹469.35. During the session, the stock traded within a range of ₹464.00 to ₹480.45, staying close to its 52-week low of ₹455.60 and well below the 52-week high of ₹640.10.

For the December quarter, Indegene reported consolidated revenue of ₹942 crore, marking a year-on-year increase of 30.8% from ₹720 crore in the same period last year. EBITDA rose 21% year-on-year to ₹160 crore, compared with ₹132 crore previously. However, EBITDA margin declined to 16.9% from 18.3% a year ago, indicating some pressure on operating profitability.

Net profit for the quarter stood at ₹103 crore, down 6.2% year-on-year from ₹110 crore in Q3 FY25.

Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.

Indegene subsidiary acquires UK firm Warn and Co for GBP 3 million

Aman Shukla — Fri, 17 Oct 2025 05:08:19 +0000

Indegene Limited is excited to announce that its wholly-owned subsidiary, Indegene Ireland Limited, has signed a Share Purchase Agreement to acquire 100% of the shares of Warn and Co Limited, a UK-based business consulting firm, on October 16, 2025.

About the Acquisition:
Warn and Co Limited, established in 2013, specializes in business transformation consulting, offering services such as change management, organizational design, and solution design to clients, including life sciences companies. The company reported an unaudited revenue of GBP 2.5 million in the last financial year (May 2024 – April 2025).

This acquisition is aimed at strengthening Indegene’s consulting capabilities in the life sciences sector, allowing the company to deliver even more comprehensive solutions to its clients. The deal is an all-cash transaction, with a total consideration not exceeding GBP 3 million, including deferred performance-based payments, and is expected to be completed by October 17, 2025.

Indegene confirms that this acquisition is not a related-party transaction, and no promoter or promoter group interests are involved. No governmental or regulatory approvals are required for this transaction.

Indegene acquires US-based BioPharm for up to USD 106 million

Aman Shukla — Wed, 01 Oct 2025 08:59:50 +0000

Indegene Limited has announced that its wholly owned subsidiary, Indegene Ireland Limited, has signed a definitive Share Purchase Agreement (SPA) to acquire 100% equity in BioPharm Parent Holding, Inc. and its subsidiaries (together referred to as BioPharm). The deal, valued at up to USD 106 million, is an all-cash transaction subject to cash and net working capital adjustments, and is expected to be completed on October 1, 2025.

BioPharm, headquartered in New Hope, Pennsylvania, is a data-driven healthcare marketing and communications agency that partners with Life Sciences companies in the North American region. Founded in August 2014, the company has built a strong reputation for delivering healthcare provider marketing solutions and employs more than 90 professionals. For the year ending December 2024, BioPharm reported revenues of USD 38.13 million (unaudited).

Indegene clarified that this acquisition does not fall under related-party transactions and that no promoter or promoter group has any interest in the deal. The acquisition is part of Indegene’s strategic plan to strengthen its omnichannel marketing agency business and expand its global capabilities in the Life Sciences sector.

Commenting on the development, the company stated that the addition of BioPharm will enhance Indegene’s service offerings for Life Sciences clients by integrating data-driven marketing expertise with its existing digital-first healthcare solutions.

The acquisition consideration includes a performance- and milestone-based component, and the transaction will be completed entirely in cash.

Indegene partners with FAST India to boost India’s biotech ecosystem

Aman Shukla — Thu, 03 Jul 2025 05:10:43 +0000

FAST India, a non-profit organisation dedicated to advancing science and technology, has entered into a strategic, long-term partnership with Indegene to strengthen India’s biotech and innovation ecosystem. This collaboration aims to scale research efforts and foster deeper collaboration between academia and the industry, creating a solid foundation for grassroots innovation.

FAST India is actively working to position the country among the top three global science and technology leaders in the next decade. The organisation runs key initiatives such as the India Science Festival, national-level science competitions, and platforms that highlight cutting-edge R&D from India and abroad.

The partnership will also support translational science and facilitate industry-academia connections through curated research, case studies, and insights. FAST India’s surveys and reports, especially those focused on students and young professionals, will play a key role in understanding public interest and shaping policies that support scientific growth.

This alliance is expected to play a pivotal role in accelerating India’s progress in biotechnology and innovation.

Indegene partners with Indian Institute of Cerebral Palsy to support disability inclusion

Aman Shukla — Mon, 19 May 2025 05:02:30 +0000

Indegene Limited has entered into a partnership with the Indian Institute of Cerebral Palsy (IICP), a nonprofit organization that works to support individuals with cerebral palsy and other disabilities. The collaboration focuses on enhancing the quality of care and accessibility for people living with disabilities in India.

Established in 1974, IICP is a registered charitable society dedicated to promoting equal opportunities and inclusive practices for marginalized groups, especially persons with disabilities. The organization offers a range of services, including education, therapy, training, and advocacy aimed at improving the quality of life for individuals with cerebral palsy.

About Indegene

Indegene Limited is a digital-first company that supports biopharmaceutical, biotech, and medical device companies throughout the product lifecycle. Its services include product development, market access, and lifecycle management using domain expertise, tailored technologies, and agile operations. The company’s solutions are designed to improve patient and physician experiences through personalized and scalable engagement across multiple channels.

Indegene expands European presence with new center in London

Aditya Bhagchandani — Wed, 19 Mar 2025 10:42:56 +0000

Indegene Limited, a digital-first life sciences commercialization company, has announced the opening of a new center in London as part of its strategic expansion in Europe. The move aims to strengthen the company’s ability to support life sciences clients in the region by offering advanced consulting and commercialization solutions with an AI-first approach.

The London center will serve as a key hub for Indegene’s European clients, allowing them to modernize operations and enhance customer engagement. The company is also expanding its workforce in the region, focusing on consulting, data analytics, engineering, and customer experience.

“London is a vital hub for healthcare, technology, and business innovation, offering a strong talent pool. With this new center, we are positioned to drive innovation and help our clients improve their commercialization processes,” said Manish Gupta, Chairman and CEO of Indegene.

This expansion follows Indegene’s recent launch of a new entity in Spain and strengthens its existing presence in Europe, which includes centers in Germany, Ireland, and Switzerland. The company has also made strategic acquisitions in the region, including Trilogy Writing & Consulting GmbH and DT Consulting, further enhancing its capabilities in medical writing and healthcare consulting.

Indegene continues to work with top biopharma companies worldwide, leveraging digital expertise to optimize product development, market access, and patient engagement solutions.

Indegene launches Cortex for life sciences industry

Aman Shukla — Mon, 24 Feb 2025 05:28:11 +0000

Indegene, a digital-first life sciences commercialization company, has introduced Cortex, a purpose-built Generative AI (GenAI) platform designed specifically for the life sciences industry. With its specialized knowledge engineering and multi-agent orchestration, Cortex enables life sciences leaders to harness and scale AI-driven transformation with enterprise-grade governance and reliability.

This groundbreaking platform plays a crucial role in streamlining high-value use cases such as optimizing the content supply chain, enhancing medical writing efficiency, and accelerating Medical-Legal-Regulatory (MLR) reviews. Cortex integrates Indegene’s 25+ years of domain expertise through advanced knowledge graphs, offering a user-friendly interface that simplifies complex processes. Unlike industry-agnostic AI solutions, Cortex is tailored to life sciences, ensuring greater accuracy, trustworthiness, and faster turnaround times.

One of its key advantages lies in its adaptability. The platform’s fit-for-purpose agents can integrate with any preferred Large Language Model (LLM) and evolve alongside AI advancements. Its multi-agent orchestration enables seamless enterprise-wide system integration, delivering measurable ROI with reduced risks. By embedding domain-specific knowledge graphs, Cortex continuously refines its understanding of life sciences workflows, driving better outcomes and efficiency.

Industry experts recognize Indegene’s pioneering role in leveraging GenAI for life sciences. HFS Research has named Indegene a Horizon 3 OneEcosystem Exponential Leader for its innovative collaborations across healthcare and life sciences. Additionally, Everest Group has acknowledged Indegene as a FrontRunner for its expertise in scaling GenAI, developing industry-specific solutions, and delivering tangible value.

Indegene expands footprint in Europe with new entity in Spain

Aditya Bhagchandani — Thu, 06 Feb 2025 06:38:18 +0000

Indegene Limited has announced the launch of its new entity in Spain as part of its ongoing strategic expansion in Europe. The digital-first life sciences commercialization company aims to leverage this new establishment to drive innovation and transformation in the life sciences sector by accelerating AI-driven commercialization processes.

The Spain entity will act as a key delivery hub for Europe-based clients, with services spanning medical affairs, data and analytics, digital marketing, creative design, and customer experience. The move aligns with the company’s goal of enhancing hyper-personalization for healthcare providers and improving patient experiences.

Key highlights:

Indegene aims to co-innovate with life sciences companies to help them modernize operations using data and AI.
The expansion builds on Indegene’s significant presence in Europe, which includes centers in the UK, Germany, Ireland, and Switzerland.
The Spain launch comes after notable acquisitions, such as Trilogy Writing & Consulting GmbH and DT Associates, to strengthen medical and regulatory capabilities.

Manish Gupta, Chairman and CEO of Indegene, emphasized Spain’s critical role as a talent and R&D hub for Europe, stating that this strategic step would enhance collaboration and innovation within the region.

With six operation hubs and 18 offices globally, Indegene continues to serve leading global biopharma and medical device companies, providing tailored solutions to meet diverse commercialization needs.

Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice.

Indegene Q3FY25 results: Revenue rises 7% YoY to Rs 720 crore, net profit up 11% to Rs 110 crore

Matrika Shukla — Thu, 30 Jan 2025 11:56:00 +0000

Indegene Limited, a healthcare solutions provider, has announced its financial results for the third quarter (Q3) of FY25, reporting strong revenue growth of 7% year-on-year (YoY) and an 11% increase in net profit. The company’s performance reflects continued expansion and operational efficiency in its core business segments.

For the quarter ending December 31, 2024, Indegene posted a consolidated net profit of ₹110 crore, compared to ₹99 crore in Q3 FY24.

Financial Highlights

Revenue from operations – ₹720 crore, up 7% YoY from ₹673 crore in Q3 FY24 and up 4.9% QoQ from ₹687 crore in Q2 FY25.
Total income – ₹758 crore, up from ₹687 crore in Q3 FY24.
EBITDA – ₹151 crore, up from ₹131 crore in Q2 FY25.
Net profit – ₹110 crore, up 11% YoY from ₹99 crore in Q3 FY24 and 20% QoQ from ₹92 crore in Q2 FY25.
Earnings per share (EPS) – ₹4.59 (basic) and ₹4.55 (diluted), up from ₹4.42 in Q3 FY24 and ₹3.84 in Q2 FY25.

Segment Performance

Indegene’s business spans Enterprise Medical Solutions, Enterprise Commercial Solutions, and Omnichannel Activation.

Enterprise Medical Solutions – ₹205 crore, up from ₹198 crore in Q2 FY25.
Enterprise Commercial Solutions – ₹400 crore, up from ₹386 crore in Q2 FY25.
Omnichannel Activation – ₹89 crore, up from ₹80 crore in Q2 FY25.

Key Updates

Indegene successfully completed its Initial Public Offering (IPO) in May 2024, raising ₹76 crore through a fresh issue of shares, along with an offer-for-sale component of ₹108 crore by existing shareholders.

The Board has approved the allotment of shares under the Employee Stock Option Plan (ESOP 2020) and Restricted Stock Unit (RSU 2020) plan, reinforcing employee participation in the company’s growth. Indegene has decided to sell its UK branch to its wholly owned subsidiary, Indegene Healthcare UK Limited, for ₹10 crore. The transaction is expected to be completed before March 31, 2025.

With a steady growth trajectory and increasing global footprint, Indegene remains an attractive investment in the healthcare solutions sector. Analysts note that the company’s rising revenue, stable margins, and global expansion strategy position it well for long-term growth.

Indegene plans to expand its healthcare technology services, invest in AI-driven solutions, and enhance its presence in international markets. The company is also focusing on strategic acquisitions to further strengthen its service offerings.

Indegene partners with CliniOps to transform clinical trial operations

Aman Shukla — Thu, 09 Jan 2025 11:22:35 +0000

Indegene, a digital-first life sciences commercialization leader, has announced a strategic partnership with CliniOps, a provider of advanced digital clinical trial solutions. This collaboration aims to revolutionize clinical trial efficiency and effectiveness globally.

With its extensive experience and a client base that includes the top 20 global pharma companies, Indegene brings life sciences-specific technology and expertise across the product lifecycle. By teaming up with CliniOps, known for its cutting-edge Unified Platform, the partnership aims to redefine clinical trial standards.

Ram Yeleswarapu, SVP, Enterprise Clinical Solutions at Indegene, stated, “This new partnership aligns with Indegene’s strategy of leveraging data and technology across the entire clinical trial value chain, with a goal to enable faster, more efficient, and cost-effective clinical development.”

Together, the two companies will focus on enhancing patient recruitment, improving data quality, and accelerating trial conduct. By combining Indegene’s domain expertise with CliniOps’ innovative solutions, the partnership is set to drive meaningful advancements in clinical trial operations.

Indegene shares fall nearly 7% after 4.7% equity worth Rs 707 crore changes hands in large block deal

Aditya Bhagchandani — Tue, 03 Dec 2024 04:11:16 +0000

Shares of Indegene Limited fell over 6% on Monday after a significant block deal involving 1.13 crore shares, amounting to 4.7% of the company’s equity, changed hands. The transaction, valued at ₹707 crore, was executed at an average price of ₹623 per share, which is at a discount to the last closing price.

The stock opened at ₹673 and dropped to ₹624.25 by 09:37 IST, a decline of ₹43.20 or 6.47%. The stock recorded an intraday low of ₹616.00, reflecting activity triggered by the large deal.

Indegene operates as a life sciences commercialization company, offering digital-led services across medical solutions, commercial solutions, and omnichannel activation.

INDEGENE LIMITED Share Price history

Day	Open	Close	Change %
Mon, Dec 2 2024	₹673.00	₹667.45	-2.17%
Fri, Nov 29 2024	₹687.70	₹682.25	-0.39%
Thu, Nov 28 2024	₹675.10	₹684.90	+1.45%
Wed, Nov 27 2024	₹670.00	₹675.10	+1.29%
Tue, Nov 26 2024	₹670.75	₹666.50	-0.09%
Mon, Nov 25 2024	₹650.00	₹667.10	+4.19%
Fri, Nov 22 2024	₹643.90	₹640.30	-0.09%
Thu, Nov 21 2024	₹638.95	₹640.90	+0.87%

As of 09:37 IST, Indegene shares were trading at ₹624.25, marking a 6.47% decline for the day.

Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.

Indegene launches new center in Hyderabad to expands global delivery network

Aman Shukla — Mon, 18 Nov 2024 08:11:00 +0000

Indegene has recently announced the launch of a new center in Hyderabad to enhance its global delivery operations. This strategic move is designed to meet the growing needs of the pharmaceutical industry and to boost its global delivery operations.

As the pharmaceutical industry is under growing pressure to innovate and adapt, this new center will play an important role in assisting companies speed up their transformation. This move fits in with Indegene’s mission: to help healthcare organizations be future-ready by combining deep medical expertise with fit-for-purpose technology.

In the exchange filing the company also shared that India is quickly becoming a major hub for global pharmaceutical companies, due to its large pool of skilled medical and technology talent. These companies are increasingly searching for a partner with core domain expertise and life sciences-contextualized technology to help them grow their operations in a non-linear, technology-driven manner.

Indegene shares surge nearly 2% as IIFL sets target price of ₹750 with ‘Add’ rating

Aditya Bhagchandani — Thu, 17 Oct 2024 04:12:34 +0000

Indegene shares saw a nearly 2% rise after IIFL initiated an ‘Add’ rating on the stock, setting a target price of ₹750, which implies a potential 8% upside from the current market price of ₹692. IIFL highlighted Indegene’s unique position in the life sciences digitization space, operating at the intersection of healthcare and technology.

IIFL expects Indegene to deliver a 12% CAGR in USD revenue and a 20% CAGR in EPS over FY24-27. However, the brokerage noted that near-term growth could be subdued due to challenges with large clients and the stock’s post-IPO rally.

As of 9:40 am, Indegene shares were trading 1.80% higher at ₹702.40 on the NSE.

Nomura initiates coverage on Indegene, expects stock to rally to upto Rs 700

Markets Desk — Mon, 23 Sep 2024 01:43:53 +0000

Nomura has initiated coverage on Indegene, assigning a “Neutral” rating and setting a target price of Rs 700, citing the company’s scalable business model and strong domain expertise as key strengths. Indegene, a leading provider of technology-led services to life sciences companies, is well-positioned to capitalize on the growing trend of digital adoption within the sector.

The brokerage highlights Indegene’s impressive client roster, which includes both large pharmaceutical firms and emerging players. This diverse clientele, coupled with a robust sales engine, suggests a strong potential for sustained growth as the industry increasingly embraces digital solutions.

Nomura also notes the strength of Indegene’s management team and its favorable rankings among industry analysts, which contribute to a positive outlook. The firm anticipates that Indegene will deliver a compound annual growth rate (CAGR) of 12% in USD revenue and 18% in earnings per share (EPS) over the fiscal years 2025 to 2027.

However, Nomura identifies several key risks that investors should consider. The company’s focus is primarily on the life sciences vertical, leading to significant exposure in a single sector. Additionally, there is a high concentration of revenue, with 46% coming from its top five clients. The use of $100 million in cash reserves without a clearly defined dividend policy further raises concerns. Furthermore, the trend of in-sourcing among clients could impact future revenue streams.

JPMorgan initiates coverage on Indegene, sets share price target at Rs 570

Markets Desk — Tue, 27 Aug 2024 02:44:12 +0000

JPMorgan has initiated coverage on Indegene, assigning a “Neutral” rating with a target price of ₹570 per share. The brokerage notes that Indegene experienced a slowdown in growth following the COVID-19 pandemic, primarily due to client-specific challenges and a weakening macroeconomic environment.

However, JPMorgan expects Indegene’s growth to rebound to early teens by FY26, projecting a stable low-teens growth trajectory thereafter. Despite this potential recovery, the firm observes that Indegene is currently trading at a premium compared to most TechOps companies and at the upper end of its mid-cap tech services peers.

Given the full valuations and uncertain visibility on new launches, JPMorgan considers the stock to be fairly priced at current levels.